Saturday, September 30, 2006

Clinical Trial

Preliminary findings by Swiss researchers have shown a once-daily oral treatment is effective in MSers, reducing relapses by more than 50%. The medication, fingolimod, prevents lymphocytes from attacking myelin.

Another phase study is recruiting across Europe, Canada, and elsewhere. If you are interested in participating, visit Novartis Clinical Trials. Be aware there are side effects including a transient reduction in heart rate after the first dose, shortness of breath, upper respiratory infections, headache and gastrointestinal problems.

If the study is successful, the oral medication could be available in three to four years.

technorati tags: , , , ,

No comments: